Latest neurofibromatosis Stories
Imagine if your brain lost its working memory â€” the ability to hold and manipulate information in your mind's eye.
Researchers have discovered how a genetic disease known mainly for its life-threatening tumors also can cause sudden death from cardiovascular disease in children, and are mounting a clinical trial to develop treatments for the problem.
Research identifies mechanism that makes cells become tumorous.
An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics.
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc.
NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September.
BELLEVUE, Wash., Aug. 12 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated drug Aptocine(TM) (talaporfin sodium) in neurofibromatosis type 1 (NF-1).
SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors.
Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2).
- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S.
- a meat pie that is usually eaten at Christmas in Quebec